Component

Overview

Product Description	ARG82733 Human CD135 / FLT3 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human CD135 / FLT3 in serum, plasma (EDTA, heparin) and cell culture supernatants.
Tested Reactivity	Hu
Tested Application	ELISA
Target Name	CD135 / FLT3
Conjugation	HRP
Conjugation Note	Substrate: TMB and read at 450 nm.
Sensitivity	50 pg/ml
Sample Type	Serum, plasma (EDTA, heparin) and cell culture supernatants.
Standard Range	62.5 - 4000 pg/ml
Sample Volume	100 µl
Precision	Intra-Assay CV: 4.8% Inter-Assay CV: 6.6%
Alternate Names	CD135; FLK2; Receptor-type tyrosine-protein kinase FLT3; FLK-2; STK-1; STK1; FL cytokine receptor; FLT-3; Stem cell tyrosine kinase 1; Fetal liver kinase-2; Fms-like tyrosine kinase 3; CD antigen CD135; EC 2.7.10.1

Application Instructions

Assay Time	~ 5 hours

Properties

Form	96 well
Storage Instruction	Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose test reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual for detail temperatures of the components.
Note	For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Database Links	GeneID: 2322 Human FLT3 Swiss-port # P36888 Human Receptor-type tyrosine-protein kinase FLT3
Gene Symbol	FLT3
Gene Full Name	fms-related tyrosine kinase 3
Background	This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015]
Function	Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways. [UniProt]
Cellular Localization	Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Note=Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation. [UniProt]
Highlight	Related products: CD135 antibodies; CD135 ELISA Kits; New ELISA data calculation tool: Simplify the ELISA analysis by GainData
PTM	N-glycosylated, contains complex N-glycans with sialic acid. Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane. Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to its proteasomal degradation. [UniProt]